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a  b  s  t  r  a  c  t
Microphthalmia-associated  transcription  factor  (MITF)  plays  a crucial  role  in the  melanogenesis  and
proliferation  of melanocytes  that is  dependent  on  its  abundance  and  modiﬁcation.  Here,  we report  that
epidermal  growth  factor  (EGF)  induces  senescence  and  cyclin-dependent  kinase  inhibitor  1A (CDKN1A)
expression  that is  related  to MITF.  We  found  that MITF  could  bind  TP53  to regulate  CDKN1A.  Furthermore,
the  interaction  between  MITF  and  TP53  is  dependent  on  AKT  activity.  We found  that  AKT  phosphorylateseywords:
ITF
KT
hosphorylation
P53
enescence
MITF  at S510.  Phosphorylated  MITF  S510 enhances  its  afﬁnity  to TP53  and  promotes  CDKN1A  expression.
Meanwhile,  the  unphosphorylative  MITF promotes  TYR  expression.  The  levels  of p-MITF-S510  are  low  in
90%  human  melanoma  samples.  Thus  the  level  of  p-MITF-S510  could  be a possible  diagnostic  marker  for
melanoma.  Our  ﬁndings  reveal  a mechanism  for regulating  MITF  functions  in  response  to  EGF  stimulation
and  suggest  a possible  implementation  for preventing  the over  proliferation  of  melanoma  cells.
© 2016  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Melanoma arises from melanocytes, and it is one of the most
reatment-resistant and notoriously aggressive human cancers
Soengas and Lowe, 2003). MITF is crucial for the growth, differen-
iation and pigment production of melanoma cells (Yajima et al.,
011). In a portion of human melanomas, MITF is an ampliﬁed
ncogene, and it also has an oncogenic element in human clear cell
arcoma (Levy et al., 2006). Melanogenesis is controlled by the three
enes, tyrosinase-related protein 1 (TYRP-1), tyrosinase-related
rotein 2 (TYRP-2) and TYR, which are all downstream of MITF
Bentley et al., 1994). Among them, TYR is a rate-limiting enzyme
n the process of melanin production (Korner and Pawelek, 1982).
ITF was identiﬁed, via integrative genomic analyses, as a lin-
age survival oncogene that was ampliﬁed in malignant melanoma
∗ Corresponding author.
E-mail address: zxliu@sibs.ac.cn (Z. Liu).
ttp://dx.doi.org/10.1016/j.biocel.2016.09.029
357-2725/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article 
/).license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
(Garraway et al., 2005). Moreover, MITF activates CDKN1A expres-
sion through cooperation with retinoblastoma 1 (RB1) to regulate
cell proliferation (Carreira et al., 2005a).
The PI3 K/AKT signaling pathway plays a central role in regu-
lating the proliferation and survival of both normal and melanoma
cells (Palmieri et al., 2015). However, activated AKT induces pro-
liferation arrest and senescence in several cell lines (Astle et al.,
2012). It has been reported that glycogen synthase kinase 3 beta
(GSK3B), a direct target of AKT, phosphorylates MITF at S298 and
enhances the expression of TYR (Takeda et al., 2000a). Many drugs
that affect PI3K/AKT activity, such as baicalin and sphingosylphos-
phorylcholine, are involved in the process of degradation of MITF
(Jeong et al., 2015; Kim et al., 2010).
TP53 is a tumor suppressor that controls the cell cycle by reg-
ulating CDKN1A, cyclin-dependent kinase inhibitor 1B (CDKN1B),
and cyclin-dependent kinase inhibitor 2A (CDKN2A) transcription
(Bieging et al., 2014). Too much or too little MITF causes cellular
senescence in many types of melanoma cells (Carreira et al., 2005a;
Strub et al., 2011). These reports indicate that regulation of cell
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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roliferation may  be associated with MITF and TP53 in melanoma
ells.
Here, we reported that AKT phosphorylates MITF at S510,
hich mediates the cellular distribution and degradation of MITF.
nphosphorylative MITF enhances TYR expression. The phospho-
ylation of MITF promotes its association with ID4 and inhibits
he expression of TYR. However, phosphorylated MITF induces
DKN1A expression and senescence in the presence of TP53 instead
f ID4 binding. MITF and p-AKT are inversely correlated in human
elanoma.
. Material and methods
.1. Antibodies and reagents
The anti-HA, anti-MITF, anti-AKT, anti-p-AKT substrate anti-
ody, anti-AKT1, anti-p-AKT-S473, anti-p-p44/42 MAPK, anti-
44/42 MAPK, anti-PTEN, and anti-EGF Receptor were from
ell Signaling Technology. The anti--tubulin was  from Santa
ruz Biotech. Total S,T phosphorylation antibody was  from BD
ioscience. The anti-MITF, anti-TP53, anti-TYR, anti-CDKN1A, anti-
amin B, anti-alpha-tubulin, and anti-GSK3 B antibodies were
rom AB Clonal Technology. PD98059, Wortmannin, PI103, and
y294002 were from Selleck Chemicals. AKTI was  from Sigma-
ldrich.
.2. Cell culture and transfection
The A375, 293A, 293T, 293FT, B16, A2059, HeLa and U87 cell
ines were purchased from ATCC and cultured in DMEM medium
ith 10% FBS and P/S in a humidiﬁed incubator at 37 ◦C with a 5%
O2 atmosphere.
For transient expression experiments, cells were transfected
ith recombinant DNA using polyethylenimine . For stable cells
ines were selected by puromycin or hygromycin B, respectively.
.3. DNA constructs and RNA interference
The human genes with HA, mGST, Myc  and Flag tags were
nserted into pRK5 using the indicated restriction enzymes. The
YR promoter in pGL3 was a gift from Prof. Colin R. Goding (Oxford
niversity, UK). The shRNA sequences for knockdown of mouse
itf, Pten and human AKT1 are listed as bellow: shMitf:  TAACCTAT-
AATACTACACCT; shPten:  TTATATCCCTTCCTTTGTGGA; shAKT1:
ACAATAGCCACGTCGCTCAT. The sgRNA of PTEN (AGATCGT-
AGCAGAAACAAA)and the sgRNA of TP53 (TGCACCAGCAGCT
CTACAC) were cloned into the modiﬁed CRISPR lentivirus vector.
. Methods
The Immunoprecipitation and Western blotting and Immuno-
istochemical staining were processed as described in (Liu et al.,
008). The CHIP assay procedure was performed as previously
eported by Dr. Saramäki (Saramäki et al., 2006). The AKT kinase
ssay was performed as previously reported(Hu et al., 2005). The
ellular fraction and luciferase assay and GST-tag proteins puriﬁca-
ion and senescence -galactosidase staining and MTT  assay were
rocedure following manufecturer’s manual. The p-MITF S510 anti-
ody was generated and puriﬁed by AB Technology.
.1. Statistical analysisStatistical signiﬁcance was measured via the unpaired and two-
ailed Student’s test and is presented as follows: *p < 0.05, **p < 0.01
nd ***p < 0.001. All error bars indicate the SEM.emistry & Cell Biology 80 (2016) 132–142 133
4. Results
4.1. AKT regulates cell proliferation and melanogenesis in
melanoma cells
The senescence or cell proliferation arrest of melanoma cells can
be induced by EGF stimulation (Leikam et al., 2014). Here, we found
that both EGF stimulation and lentiviral infection with epidermal
growth factor receptor (EGFR) can induce CDKN1A expression and
reduce TYR in melanoma cells (Fig. 1A, B). To conﬁrm these results,
we inhibited AKT. The abundance of CDKN1A in AKTI-treated B16
cells is less than that of cells treated with EGF. However, the abun-
dance of TYR in AKT inhibitor-treated B16 cells is higher than that
of cells treated with EGF (Fig. 1C). The MTT  assay revealed that EGF
stimulation prevents the proliferation of B16 cells (Fig. 1D).  After
treatment with EGF, the cells exhibit senescence and relatively high
beta-Gal activity (Fig. 1E). AKT is associated with cell senescence
(Astle et al., 2012). We  hypothesized that MITF is a substrate of
AKT. To conﬁrm our hypothesis, we  detected total phosphoryla-
tion of MITF after inhibition or stimulation of AKT. We  found that
phosphorylation of MITF depends on AKT activity (Fig. 1F). These
results suggest that MITF is a target of AKT.
4.2. MITF is phosphorylated by AKT at serine 510
To assess whether MITF could be phosphorylated by AKT, we
performed in vitro and in vivo kinase assays. GST-MITF or GST only
was cotransfected with HA-AKT-CA (constitutively active AKT). A
p-AKT-substrate antibody was  used to detect MITF phosphoryla-
tion. A clear band was  observed in the GST-MITF panel, but no signal
was detected for GST only (Fig. 2A). Similar results were obtained by
cotransfecting GST-MITF with HA-AKT-CA or HA vector as shown in
Fig. 2B. The phosphorylation of MITF was reduced by PI3 K and AKT
inhibitors even with EGF stimulation. However, MITF phosphory-
lation was not suppressed by an ERK inhibitor (Fig. 2C). These data
indicated that AKT phosphorylates MITF.
Based on the literature, AKT recognition motif is
(R/K)X(R/K)XX(S/T), where X is any amino acid. Several con-
served AKT substrate motifs were found in MITF. We  have
identiﬁed that TFEB, a MITF family member, could be phospho-
rylated by AKT at S467 (data not shown). We aligned the amino
acid sequences of the four members of the MITF gene family. A
conservative AKT substrate motif can be found in the C-terminal
of this family (Fig. 2D). Alanine scanning was used to accurately
identify the phosphorylation site, and S510 of MITF was  found
to be a precise site (Fig. 2E). The in vitro kinase assays were
performed to determine whether MITF is the direct target of
AKT and whether S510 is the phosphorylation site. Using the
p-AKT-substrate antibody and autoradiography of -32P-ATP, the
results showed that AKT could phosphorylate MITF in vitro but
not the MITF S510A mutant (Fig. 2F, G). MITF WT  and S510A were
transfected into HEK293T cells and then treated with or without
EGF. The pull-down was  determined using the p-AKT substrate
antibody. No signal was  detected in the S510A pull-down even
with EGF treatment. This suggests that S510 is a phosphorylation
site of AKT in vivo (Fig. 2H). To conﬁrm this, we  generated a speciﬁc
antibody that was tested by recognizing the exogenous GST-MITF
WT but not GST-MITF S510A (Fig. 2I). p-MITF was detectable with
this antibody after EGF stimulation in B16 cells but not in PI3K and
AKT inhibitor-treated cells (Fig. 2J). Similar results were observed
in A2059 cells (Fig. 2K). PTEN is upstream of AKT and inhibits
the PI3K/AKT pathway. When we  knockdown PTEN, endogenous
phosphorylation of MITF is augmented (Fig. 2L). We  next asked
where phosphorylation of MITF by AKT occurs. To answer this
question, we cotransfected GST-MITF with NLS-AKT or Myr-AKT,
and the cell lysate was determined using the p-MITF antibody.
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Fig. 1. AKT regulates cell proliferation and melanogenesis in melanoma cells.
(A)  B16 cells were treated with EGF or PBS overnight. The expressions of proteins were analyzed by WB.  (B) CDKN1A and TYR expression levels were determined after EGFR
overexpression. (C) B16 cells were treated with or without AKTI. Then, the cell lysates were subjected to IB analysis. (D) The cell viability was determined by MTT  assay after
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t16  cells were treated with EGF. Values are presented as the mean ± SEM, n = 3,*p <
F)  HEK293FT cells were transfected with the mGST-MITF plasmid and treated with
ntibodies.
he result showed that only Myr-AKT can phosphorylate MITF
Fig. S1A). Then AKT phosphorylates MITF in cytoplasm. All these
esults suggest that MITF is directly phosphorylated by AKT.
.3. TYR and CDKN1A are regulated by phosphorylation of MITF
TYR and CDKN1A are the two most important genes down-
tream of MITF (Carreira et al., 2005a). We  have already observed
hat the levels of TYR and CDKN1A are altered with EGF treat-
ent. MITF is also phosphorylated by AKT; therefore, we  speculated
hether TYR and CDKN1A expression levels are affected by MITF
hosphorylation. To determine the effect of MITF phosphoryla-
ion on TYR expression, we knocked down endogenous MITF by
argeting its 3′ UTR, which will not affect exogenous MITF expres-
ion with only CDS. Additionally, we rescued the expression of
ITF WT,  S510A, S510D mutants by transfection. Western blot-
ing revealed that the unphosphorylative mutant S510A enhanced
YR expression compared to MITF WT;  however, the phosphory-
ated mimic  S510D reduced TYR expression (Fig. 3A). We  analyzed
hether the expression of TYR corresponded to the activation of
he PI3K/AKT signaling pathway. Both EGF and insulin stimula-
ion activated the PI3K/AKT pathway and decreased TYR expression(E) B16 cells were treated with or without EGF and stained with beta–Gal reagent.
dicated drugs. The cell lysates were used in the IB and IP assays with the indicated
compared to PI3K/AKT inhibition (Fig. 3B). The above results were
veriﬁed by a subsequent luciferase assay, and the ability to suppress
TYR expression was  demonstrated by either the S510D mutant or
by simulations with EGF/insulin (Fig. 3C,D). The S510A mutant or
AKT inhibition increased luciferase readout compared to its coun-
terparts (Fig. 3C,E).
To explore whether CDKN1A expression is also regulated by
MITF phosphorylation, we overexpressed MITF variants in HeLa
cells. Overexpression of the S510D mutant increased CDKN1A com-
pared to its counterparts (Fig. 3F). This result was  conﬁrmed by
luciferase assay (Fig. 3G). The U87 cells were infected by the indi-
cated exogenous lentivirus expressing MITF variants. CDKN1A was
increased by MITF S510D infection (Fig. 3H). These results demon-
strated that phosphorylation of S510 can regulate the two most
important genes downstream of MITF.
4.4. Phosphorylation of MITF by AKT induces its degradationIt has been reported that phosphorylation inﬂuences the stabil-
ity of proteins (Swaney et al., 2013). Therefore, we ﬁrst examined
the stability of MITF after its phosphorylation. The MITF WT and
its variants were transfected into HEK293T cells. Then, the cells
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Fig. 2. AKT phosphorylates MITF at S510 in vivo and in vitro.
(A)MITF is phosphorylated by AKT. The indicated plasmids were transiently transfected into HEK293FT cells, followed by glutathione bead pull-down and IB. The phos-
phorylation of MITF was determined using p-AKT substrate antibody. (B) GST-MITF was  transfected with HA-AKT-CA or HA Vector. The glutathione bead pull-down was
immunoblotted with p-AKT substrate antibody. (C) HEK293FT cells were transfected with GST-MITF and pretreated with indicated inhibitors. The cells were stimulated with
or  without EGF, and the cell lysates were subjected to IP and IB with the indicated antibodies. (D) Schematic alignment of the protein sequences of MITF family proteins. (E)
Ala  scanning showed that serine 510 of MITF is the solo phosphorylation site. (F–G) HA-AKT-CA was  transfected into HEK293FT cells and immunoprecipitated via HA beads.
Recombinant GST-MITF and GST-MITF-S510A protein are puriﬁed from bacteria. Phosphorylation of S510 was  identiﬁed by the p-AKT substrate antibody (F) or autoradiog-
raphy  (G). (H) GST-MITF and GST-MITF-S510A were transfected into HEK393 cells with or without EGF stimulation. Cell lysates were harvested for IP and IB analysis with the
indicated antibodies. (I) WT and S510A were transfected into HEK293FT cells, and cell lysates were analyzed by IB via the p-MITF S510 speciﬁc antibody. (J–K) Identiﬁcation
of  endogenous phosphorylation of S510 in melanoma cells. B16 or A2059 cells were pretreated with indicated inhibitors and stimulated by EGF, followed by IB analysis with
the  indicated antibodies (J, K). (L) A2059 cells were infected with control or sgPTEN lentivirus. Then, cell lysates were harvested for IB analysis using the indicated antibodies.
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Fig. 3. Phosphorylation of MITF regulates TYR and CDKN1A expression levels.
(A) B16 cells were established as stable cell lines to knockdown Mitf by targeting the 3′ UTR of Mitf mRNA, named shB16. shB16 cells were infected with lentivirus expressing
MITF  WT,  S510A and S510D, and TYR expression was  determined. (B) GST-MITF was transfected into HEK293FT cells and treated with the indicated drugs. The whole-cell
lysates were analyzed by IB with the indicated antibodies. (C) The luciferase activities of TYR luciferase reporters were measured and normalized after overexpressions of
MITF,  WT,  S510A and S510D, respectively. The experiments were performed in triplicate, and the data were expressed as the mean ± SEM of 3 independent experiments.
Values are presented as the mean ±SEM, n = 3,*p < 0.05. The data was  analyzed using Graph pad prism 5. (D) The cells were treated with PBS, insulin and EGF, respectively.
The  following measurement and data analysis are the same as in Fig. 3C. (E) The pGL3-TYR promoter was transfected into B16 cells. Then, the cells were treated with AKTI
or  DMSO. The analysis of the data is identical to the results that were shown in Fig. 3C. ***p < 0.001. (F) HeLa cells were transfected with SFB-MITF WT,  S510A, and S510D.
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ells,  respectively. After 24 h, the luciferase activity was detected and calculated. S
ig. 3C. *p < 0.05,***p < 0.001.
ere treated with cycloheximide (CHX) for the indicated times.
he cell lysate was immunoblotted with the indicated antibody.
ITF S510D degraded much faster than WT  and S510A (Fig. 4A,
ig. S1B). These data revealed that phosphorylation at S510 caused
ITF instability. We speculated whether this instability was  due
o increased ubiquitination of MITF. We  transfected the GST-MITF
T S510A and S510D into HEK293T cells. The cell lysates were
ulled down using glutathione beads and the pull-down com-
lex was determined using an anti-ubiquitin antibody after MG132
reatment. The result showed that the intensity in the S510D panel
as much higher than that of its counterparts (Fig. 4B). To conﬁrm
hat its stability was correlated with the phosphorylation by AKT,
e conducted a time-course treatment of the cells with or without
KTI combined with CHX. p-MITF and total MITF were examined.
he stability of MITF was augmented when the cells were treated
ith AKTI (Fig. 4C). Knockdown of PTEN also reduced MITF and TYRFig. 4D). These results indicate that AKT-mediated phosphoryla-
ion of MITF led to degradation through the proteasome pathway.N1A promoter was co-transfected with SFB-MITF WT,  S510A and S510D into HeLa
uent calculations and data analysis are consistent with the previous description in
4.5. The cellular distribution of MITF is affected by
phosphorylation
To determine whether phosphorylation of MITF inﬂuences its
localization, we took images and separated the cellular fractions
with different treatments and different variants transfections. The
B16 or A2059 cells were treated with EGF or AKTI, then the cells
were fractionized and MITF was  examined. MITF was  translo-
cated to the nucleus from the cytoplasm when AKT was inhibited
(Fig. 4E; Fig. S1C). Images of exogenous GFP-MITF WT,  S510A and
S510D revealed that S510A was much more highly concentrated
and brighter in the nucleus than WT  and S510D. However, WT  and
S510D were distributed in both the cytoplasm and the nucleus, but
S510D was much weaker (Fig. 4F). We  have demonstrated that AKT
inhibition or the S510A mutant induces nuclear translocalization.4.6. p-MITF binds ID4 to inhibit TYR expression
We  have demonstrated that the phosphorylation of MITF
decreased TYR expression. We  next wanted to dissect the molecular
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Fig. 4. Phosphorylation of MITF induced its degradation and change in cellular distribution.
(A)SFB-MITF WT,  S510D and S510A were transfected into HEK293FT cells and treated with cycloheximide (CHX) for the indicated time. Then, whole-cell lysates were
harvested for the following IB experiment. (B) MITF-S510D was  degraded rapidly by an ubiquitin-mediated pathway. (C) B16 cells were pretreated with or without AKTI
following CHX treatment for a time course. The lysates were analyzed with the indicated antibodies. The gray scale of MITF was calculated using Image J. The numerical
value  of the vertical coordinates is the ratio. The data were analyzed using Graph pad prism 5. Values are shown as the mean ± SD. n = 2, *p < 0.05. (D) MITF is reduced in the
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ShPten  B16 stable line compared with the control. (E) MITF moved into the cytoplas
F)  Images of EGFP-MITF WT,  S510D and S510A in HeLa cells by ﬂuorescence micro
echanisms by which MITF phosphorylation regulates TYR expres-
ion. Inhibitor of DNA-binding/differentiation proteins are a class
f proteins that bind to proteins that contain bHLH domains and
nhibit the binding of bHLH to DNA and disrupt its transcriptional
apabilities (Zebedee and Hara, 2001). The gene family consists of
our members: ID1, ID2, ID3 and ID4. Here, we showed that the
nteraction between MITF and ID4 is the strongest in the ID gene
amily (Fig. 5A). Even S510D interacted more strongly with ID4 than
510A and WT  (Fig. 5B). MITF lost its ability to transcriptionally acti-en treated with an AKT inhibitor, which was the opposite effect of EGF stimulation.
.
vate TYR when it was bound to ID4, which was  shown via luciferase
assay (Fig. 5C). ID4 has the strongest inhibitory effect on S510D in
terms of TYR (Fig. 5D, E). These data demonstrated that p-MITF
inhibits TYR expression through binding to ID4.4.7. p-MITF interacts with TP53 to regulate CDKN1A expression
A high level of MITF in melanoma cells can induce the expres-
sion of CDKN1A, and MITF is associated with cell senescence in
138 C. Wang et al. / The International Journal of Biochemistry & Cell Biology 80 (2016) 132–142
Fig. 5. Phosphorylation of MITF enhances the interaction with ID4 and reduces TYR expression.
(A)MITF binds to ID4. GST-MITF was co-transfected with ID family members into HEK293FT cells. Then, whole-cell lysates were used for IP and IB. (B) S510D binds more ID4.
(C)  SFB-MITF-WT and PGL3-TYR promoter were transfected into HEK293FT cells with/out Myc-ID4. The luciferase activities were assayed and analyzed. Values are shown as
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nd  S510A, respectively. The following experiments and data analysis are identica
T,  S510D and S510A. Then, the cell lysates were analyzed by IB.
arious melanoma cell lines (Carreira et al., 2005a; Strub et al.,
011; Giuliano et al., 2010). We  speculated which proteins would
nteract with MITF to regulate CDKN1A. We  used the IP method
o determine which proteins may  be involved in MITF’s increase
DKN1A at the transcriptional level as reported in literature, such
s Retinoblastoma 1 (RB1), catenin beta 1 (CTNNB1), and TP53. We
ound that TP53 and RB1 can bind to MITF (Fig. 6A). But the afﬁnity
f TP53 to MITF S510D is increased (Fig. 6F). So we believed that
-MITF regulating CDKN1A is mediated by TP53. When TP53 was
nocked out, CDKN1A was undetectable (Fig. 6B). We  found that,
f the MITF family members, only MITF can interact with TP53 (Fig.
1D). We  truncated TP53 and MITF and found that the HLH domain
f MITF and the DNA-binding domain of TP53 contribute to their
nteraction (Fig. 6C,D). Inhibition of the phosphorylation of MITF by
n AKT inhibitor attenuated the interaction between MITF and TP53
Fig. 6E). As we demonstrated above, ID4 and TP53 could interact
ith p-MITF, respectively. We  next wanted to know whether ID4
nd TP53 compete or cooperate. To answer this question we  trans-
ected GST-MITF S510D and myc-ID4 in the presence or absence of
A-TP53. The result showed that ID4 binds less MITF S510D in the
resence of TP53 (Fig. 6G). This revealed that TP53 competed with
D4 to bind MITF S510D. It has been reported that TP53 binds to sev-
ral regions of the CDKN1A promoter (Saramäki et al., 2006). CHIP
ssays were carried out using the MITF antibody and correspond-
ng primers, which recognized different regions of the CDKN1A
romoter as reported by Dr. Saramäki. The result indicated that
ITF and TP53 bind to the same regions of the CDKN1A promoter
Fig. 6H). Compared to MITF WT  and S510A, MITF S510D enhances
he binding ability of TP53 to the CDKN1A promoter (Fig. 6I). There-
ore, we concluded that, after phosphorylation by AKT, MITF is likely
o interact with TP53 and leads to the expression of CDKN1A and
revents cell proliferation.
.8. Phosphorylation of MITF causes cell proliferation arrest and
enescence
Previous data indicate that p-MITF prevents cell proliferation.
e established inducible stable cell lines of the MITF variants.
ell viability was measured by the MTT  assay. The results showed
hat all of the MITF variants could induce cell proliferation arrest;
owever, S510D had a stronger effect (Fig. 7A). When B16 cells-TYR promoters were co-transfected into HEK293FT cells with SFB-MITF WT,  S510D
ose in Fig. 5C. (E) SFB-ID4 was co-transfected into HEK293FT cells with GST-MITF
were cotransfected with lentivirus expressing MITF variants and
shMitf for 72 h and beta-Gal staining was performed, much more
blue staining was observed in the S510D-infected cells. This indi-
cated that S510D induced more cell senescence (Fig. 7B). Some
researchers believe that cancer is a kind of parasitic organism; to
survive, they are unscrupulous. Based on this opinion, we  believe
that melanoma is not excluded. To survive, they chose to weaken
the activity of AKT. If this is the case, p-AKT and MITF should exhibit
an inverse relationship. To determine whether this is the case, we
performed immunohistochemical staining of p-AKT-S473 and MITF
on melanoma slices from patients. We  stained samples from 16
patients who  had melanoma in their skin (Supplemental Table 1).
The representative images are shown in Fig. 7C. We  found that 90%
of the melanoma samples showed an inverse relationship between
p-AKT and MITF and positive relationship between p-AKT and p-
MITF (Fig. 7C). In a small number of samples, such as sample number
15-24690, some regions showed a lower MITF/p-AKT ratio rela-
tive to the negative control (Fig. 7C). This result is consistent with
our observation in cell lines. This indicates that in high number of
MITF melanoma cells, the AKT activity will be reduced to avoid cell
senescence through phosphorylation of MITF.
5. Discussion
We  found that EGF could cause proliferation arrest and cell
senescence of melanoma cells. The genes CDKN1A and TYR were
controlled by AKT. AKT directly phosphorylates MITF at S510. The
phosphorylation led to proteasome-mediated MITF degradation,
which was  concomitant with proliferation arrest and senescence.
The unphosphorylative MITF translocates to the nucleus and pro-
motes TYR expression. The phosphorylative mimic S510D localizes
to both the cytoplasm and the nucleus and enhances CDKN1A
expression. We  also demonstrated that MITF S510D binds to ID4  to
inhibit the transcription of TYR. In the presence of TP53, TP53 would
compete with ID4 to bind MITF S510D. The p-MITF/TP53 complex
binds to the CDKN1A promoter and transiently enhances CDKN1A
expression in response to AKT activation. Our work explains the
dual role of MITF in regulating melanoma progress (Fig. 7D).
It has been reported that phosphorylation of MITF at S73 by
ERK also leads to CDKN1A expression and MITF instability (Kim
et al., 2010; Wu et al., 2000a; Liu et al., 2010). P90-RSK1, which
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Fig. 6. Phosphorylated MITF interacts with TP53 and induces CDKN1A expression.
(A) MITF binds TP53 in vitro. GST-MITF and HA-TP53 were transfected into HEK293FT cells and whole-cell lysates were subjected to GST pull-down and IB with the indicated
antibodies. (B) Deletion of TP53 blocked the expression of CDKN1A. (C) The fragments of MITF were co-transfected with HA-TP53 into HEK293FT cells, followed by the IP
and  IB experiments. (D) MITF interacts with TP53 94–300. The diagram of TP53 fragments is shown in the top panel. (E) B16 cells were incubated with or without AKTI.
The  lysates were IPed with the MITF antibody and analyzed with the TP53 antibody. (F) MITF S510D strongly interacts with TP53. The indicated plasmids were transfected
into  HEK293 cells, followed by IP and IB analysis using the corresponding antibodies. (G) TP53 competes with ID4 in binding MITF. Myc-ID4 and mGST-MITF-S510D were
co-transfected with or without HA-TP53 into HEK293FT cells, followed by downstream experiments and data analysis. (H) The CHIP assay was performed using the MITF
antibody following the manufacturer’s instructions. PCR was performed using speciﬁc primers. (I) The indicated plasmids were transfected into MGH  cells, then the cells
were  subjected to the subsequent procedures as described in Fig. 6H. The gray scale was  calculated using Image J. Then, the data were subjected to analysis via Graph pad
prism  5. Mean ± SEM. *p < 0.05.
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Fig. 7. Phosphorylation of MITF induces senescence.
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pA) Stable B16 cells were infected with inducible lentivirus of MITF variants and se
erformed. The data analysis is identical to that presented in Fig. 1E. Values are pres
ells  infected with MITF WT,  S510D and S510A lentivirus. (C) The representative im
s the direct target of BRAF-V600E, phosphorylates MITF at S409
nd causes its degradation (Wu  et al., 2000b). Our observations of
hosphorylation at S510 of MITF are similar to the observations of
hosphorylation of MITF at S73 and S409. Here, we found that AKT
hosphorylates MITF at S510, which triggers its degradation. This by puromycin. After inducing expression of the MITF variants, the MTT  assay was
 as the mean ± SEM, *p < 0.05, ***p < 0.001. (B) Images of beta-Gal staining of shB16
f p-AKT and MITF in human melanomas. (D) Flowchart of the model.
phosphorylation leads to transient expression of its downstream
target CDKN1A and reduces TYR transcription.
Tyrosinase is the limiting step for melanin synthesis, which
is controlled by MITF (Slominski et al., 2004). Melanin is lost
during PI3K/AKT activation (Lee et al., 2012; Song et al., 2015)
and TYR is downregulated by EGF treatment (Shin et al., 2014).
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SK3phosphorylates MITF at S298 and blocks its transcriptional
ctivation of TYR (Takeda et al., 2000b; Khaled et al., 2002). More
elanin was produced in B16 cells when AKT was  inhibited (Huang
t al., 2014). All of our ﬁndings are consistent with these results,
nd these data are related to MITF phosphorylation. We  found
ITF S510A could induce melanin production by upregulating TYR
xpression. Thus we demonstrated the insight mechanism that AKT
egulates Melanin production. Unphosphorylative MITF is much
ore stable than the WT  and phosphorylative forms. We  found
hat phosphorylated MITF bound more ID4, which inhibits the tran-
criptional activation of TYR by MITF.
Cellular senescence is an irreversible proliferation arrest that is
ctivated by various cellular and molecular stresses (Ben-Porath
nd Weinberg, 2004; Campisi, 2005). Senescence or proliferation
rrest could be induced by oncogenes such as KRAS mutations in
ormal human and mouse cells in culture (Vicent et al., 2010).
I3K/AKT is also an inducer of senescence (Astle et al., 2012;
ennedy Ras et al., 2014; Sun et al., 2014). Consistent with pre-
ious reports, we observed cell proliferation arrest as a result of
I3K/AKT activation in B16 melanoma cells. CDKN1A is a predom-
nant inducer of cell proliferation arrest and senescence (Kuilman
t al., 2010). Here, we found that CDKN1A is dramatically upreg-
lated with EGF stimulation. The S510D mutant also increased
DKN1A expression and senescence.
Normally, cell senescence is related to RB1 and TP53 (Benhamed
t al., 2012; Qian and Chen, 2013; Chen et al., 2005). Indeed, the
bility of MITF to regulate CDKN1A is likely to be highly complex,
ith many factors contributing directly or indirectly to the regula-
ion of CDKN1A expression by MITF (Carreira et al., 2005b, 2000).
owever, we did not observe any differences in the interactions
etween WT,  S510A, S510D and RB1 (data not show). Meanwhile,
ITF still upregulated CDKN1A even after knockdown of RB1. It
s indicated that this phosphorylation regulating CDKN1A expres-
ion is not mediated by RB1. Actually, we discovered that p-MITF
irectly binds TP53 to regulate CDKN1A expression and that p-MITF
oes not bind ID4 in the presence of TP53.
In normal skin cells, p-AKT and MITF are moderately expressed
http://www.proteinatlas.org), and we believe that MITF is in a
ontrolled transcriptional state to maintain normal physiological
unction. Here, we identiﬁed an important role of MITF in response
o EGF stimulation and dissected the mechanism by which MITF
egulates CDKN1A and TYR. MITF and p-AKT exhibit an inverse
elationship in patient samples. p-MITF-S510 is an alternative
iagnostic marker for human melanoma. Our results help us to
nderstand the multiple roles of MITF in melanoma and open up a
ew avenue for the treatment of melanoma.
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